Skip to main content

Mzodidi Tutuka (32317292/2020)

Paper Title

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.

Pubmed ID
32317292
Date
2020/04/22
Member Group
SADaCC
Member Name
Mzodidi Tutuka
First Author
Jonathan S Cebon
First Author Affiliation
Cancer Immunobiology Programme, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University at Austin Health, Heidelberg, Victoria, Australia j.cebon@onjcri.org
Last Author
Weisan Chen
Last Author Affiliation
Ludwig Institute for Cancer Research Austin Branch, Heidelberg, Victoria, Australia